Slideshows Images Quizzes

Lorabid

Last reviewed on RxList: 12/8/2004
Please Note: This Brand Name drug is no longer available in the US. (Generic versions may still be available.)
Lorabid Side Effects Center

Last reviewed on RxList 1/22/2016

Lorabid (loracarbef) is an antibiotic used to treat many different types of infections caused by bacteria. The brand name Lorabid is discontinued, but generic versions may be available. Common side effects of Lorabid (loracarbef) include itching or skin rash, nausea, vomiting, stomach pain or cramps, loss of appetite, diarrhea, flushing (warmth, redness, or tingling under your skin), headache, dizziness, drowsiness, vaginal itching or discharge, runny or stuffy nose, rash, or drowsiness.

Dosage of Lorabid depends on the disease being treated. Lorabid may interact with probenecid, or diuretics. Tell your doctor all medications and supplements you use. Lorabid is not expected to be harmful to a fetus. Tell your doctor if you are pregnant or plan to become pregnant during treatment. It is unknown if this drug passes into breast milk or if it could harm a nursing baby. Consult your doctor before breastfeeding.

Our Lorabid (loracarbef) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Lorabid Consumer Information
SIDE EFFECTS: Consult your pharmacist.

In the US -

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

Read the entire patient information overview for Lorabid (Loracarbef)

Lorabid Professional Information

SIDE EFFECTS

The nature of adverse reactions to loracarbef are similar to those observed with orally administered b-lactam antimicrobials. The majority of adverse reactions observed in clinical trials were of a mild and transient nature; 1.5% of patients discontinued therapy because of drug-related adverse reactions. No one reaction requiring discontinuation accounted for >0.03% of the total patient population; however, of those reactions resulting in discontinuation, gastrointestinal events (diarrhea and abdominal pain) and skin rashes predominated.

All Patients

The following adverse events, irrespective of relationship to drug, have been reported following the use of loracarbef in clinical trials. Incidence rates (combined for all dosing regimens and dosage forms) were less than 1% for the total patient population, except as otherwise noted:

Gastrointestinal: The most commonly observed adverse reactions were related to the gastrointestinal system. The incidence of gastrointestinal adverse reactions increased in patients treated with higher doses. Individual event rates included diarrhea, 4.1%; nausea, 1.9%; vomiting 1.4%; abdominal pain, 1.4%; and anorexia.

Hypersensitivity: Hypersensitivity reactions including, skin rashes (1.2%), urticaria, pruritus, and erythema multiforme.

Central Nervous System: Headache (2.9%), somnolence, nervousness, insomnia, and dizziness.

Hemic and Lymphatic Systems: Transient thrombocytopenia, leukopenia, and eosinophilia.

Hepatic: Transient elevations in AST (SGOT), ALT (SGPT), and alkaline phosphatase.

Renal: Transient elevations in BUN and creatinine.

Cardiovascular System: Vasodilatation.

Genitourinary: Vaginitis (1.3%), vaginal moniliasis (1.1%).

As with other b-lactam antibiotics, the following potentially severe adverse experiences have been reported rarely with loracarbef in worldwide post-marketing surveillance: anaphylaxis, hepatic dysfunction including cholestasis, prolongation of the prothrombin time with clinical bleeding in patients taking anticoagulants, and Stevens-Johnson syndrome.

Pediatric Patients

The incidences of several adverse events, irrespective of relationship to drug, following treatment with loracarbef were significantly different in the pediatric population and the adult population as follows (TABLE 12):

TABLE 12
Event Pediatric Adult
 Diarrhea 5.8% 3.6%
 Headache 0.9% 3.2%
 Rhinitis 6.3% 1.6%
 Nausea 0.0% 2.5%
 Rash 2.9% 0.7%
 Vomiting 3.3% 0.5%
 Somnolence 2.1% 0.4%
 Anorexia 2.3% 0.3%


b-Lactam Antimicrobial Class Labeling

The following adverse reactions and altered laboratory test results have been reported in patients treated with b-lactam antibiotics:

Adverse Reactions: Allergic reactions, aplastic anemia, hemolytic anemia, hemorrhage, agranulocytosis, toxic epidermal necrolysis, renal dysfunction, toxic nephropathy. As with other b-lactam antibiotics, serum sickness-like reactions have been reported rarely with loracarbef.

Several b-lactam antibiotics have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced. If seizures associated with drug therapy should occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.

Altered Laboratory Tests: Increased prothrombin time, positive direct Coombs' test, elevated LDH, pancytopenia, and neutropenia.

Read the entire FDA prescribing information for Lorabid (Loracarbef)

Related Resources for Lorabid

Read the Lorabid User Reviews »

© Lorabid Patient Information is supplied by Cerner Multum, Inc. and Lorabid Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors